Danaher had a disappointing 2024. Your path to success next year passes through Wall Street
Life sciences company Danaher certainly hasn't been an easy stock to buy this year. A wave of new companies going…
Biotechnology and pharmaceuticals
Eli Lilly seeks to extend its winning streak in the general market to 6 years
Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street realized its huge opportunity in obesity…
FDA Approves Eli Lilly's Zepbound Weight-Loss Drug for Sleep Apnea
An Eli Lilly & Co. Zepbound injection pen placed in the Brooklyn borough of New York, U.S., on Thursday, March…
Merck signs weight loss pills licensing agreement with Hansoh Pharma
Exterior view of the entrance to Merck headquarters on February 5, 2024 in Rahway, New Jersey. Spencer Platt | fake…
Eli Lilly's Zepbound Weight Loss Drug No Longer in Shortage
An injectable pen of Zepbound, Eli Lilly's weight loss drug, is on display in New York City on December 11,…
Ozempic faces scrutiny over possible risk of eye condition
A box of Ozempic manufactured by Novo Nordisk is seen in a pharmacy in London, Britain, March 8, 2024. Hollie…
We're adding to our position in a stock that just got some big support from Wall Street.
Shortly after the bell rings, we will buy 300 shares of Bristol Myers Squibb at approximately $56.50. Following the deal,…
UnitedHealth Group CEO Andrew Witty Addresses Death of Brian Thompson
Andrew Witty, CEO of UnitedHealth Group, testifies during the Senate Finance Committee hearing titled “Hacking America's Health Care: Assessing Cyberattack's…
We want to increase our ownership of a portfolio stock that just increased its dividend.
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Ro to Offer Zepbound Vials of Weight Loss Drug Working with Eli Lilly
Patients will be able to access Zepbound single-dose vials in Ro Courtesy: Ro Direct-to-consumer healthcare startup Ro said Wednesday that…